Objective: To investigate the association between three single nucleotide polymorphisms (SNPs) of the vascular endothelial growth factor (VEGF) gene and the risk of glioma in a Han Chinese population. Methods: This hospital-based case-control study used polymerase chain reaction-restriction fragment length polymorphism analysis to detect three SNPs (À634 G/C, þ936 C/T and þ1612 G/A) of the VEGF gene in patients with glioma compared with healthy control subjects. Results: The study investigated 880 patients with gliomas and 880 age-and sex-matched healthy control subjects. Patients with gliomas had a significantly higher frequency of the À634 CC genotype (odds ratio [OR] 1.35, 95% confidence interval [CI] 1.05, 1.75) and the þ936 TT (OR 1.73, 95% CI 1.20, 2.48) genotype compared with the control subjects. Patients with glioblastomas had a significantly higher frequency of the À634 CC and þ936 TT genotypes. Patients with grade IV gliomas had a significantly higher frequency of the À634 CC and þ936 TT genotypes. The þ1612 G/A polymorphisms were not associated with glioma risk. Conclusion: The VEGF À 634 CC and þ936 TT genotypes were associated with a higher risk of glioma in a Han Chinese population.
Introduction
Gliomas are the most common primary tumours of the central nervous system, but in spite of marked advances in the characterization of their molecular pathogenesis, these tumours remain incurable. 1 Estimated 5-year survival rates are 60% for biopsy and watchful waiting and 74% for early resection in low-grade gliomas. 2, 3 Gliomas can be classified into four World Health Organization (WHO) clinical grades (I, II, III and IV) based on histopathological characteristics and biological behaviour. 4 This group of tumours includes specific histological subtypes, the most common of which are the astrocytomas, glioblastomas and other gliomas. 5 Although many studies have been conducted on the aetiology of gliomas, it is still not completely understood. Several occupations, 6, 7 environmental carcinogens 8 and diet have been reported to be associated with an elevated glioma risk. 9 Genome-wide association studies have reported that single nucleotide polymorphisms (SNPs) are associated with glioma susceptibility. 10, 11 However, additional factors that contribute to glioma susceptibility require further investigation.
Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development and progression of solid tumours. 12, 13 The VEGF gene is located on chromosome 6p21.3 and consists of eight exons that exhibit alternative splicing to form a family of proteins. 14 Several SNPs in the VEGF gene have been shown to affect the expression of the gene. 15, 16 Three potentially functional SNPs (À634 guanine [G]/cytosine [C], þ936 C/thymine [T] and þ1612 G/adenine [A]) in the 3'-untranslated region (3 0 UTR) of the VEGF gene were shown to affect plasma VEGF levels. 17 VEGF gene polymorphisms have been reported to be associated with lung, 18 colorectal, 19 breast, 20 oral, 21 ovarian, 22 gastric and bladder 23, 24 cancer.
Despite these data in other tumours, [18] [19] [20] [21] [22] [23] [24] few studies have been done on the associations between these three SNPs (À634 G/C, þ936 C/T and þ1612 G/A) of the VEGF gene and the risk of glioma. 25, 26 The purpose of this present study was to investigate whether there are any associations between these three SNPs of the VEGF gene and the risk of glioma in a Han Chinese population.
Patients and methods

Study population
This hospital-based case-control study enrolled consecutive patients with newly diagnosed and histologically confirmed glioma recruited at the Department of Neurosurgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China between January 2009 and January 2013. The patients were all Han Chinese from the same geographical region. Tumour histological type and grade were determined according to the WHO criteria. 4, 5 Inclusion criteria for the patients with glioma included: (i) <65 years at diagnosis; (ii) complete medical records were available; (iii) diagnosed <1 year before the registration date; (iv) provided written informed consent to participate in the study. Patients who had tumour recurrence or progression at the time of registration or who were <20 years of age at diagnosis were excluded. The healthy control subjects were recruited from the Department of Neurosurgery, First Affiliated Hospital of Xi'an Jiaotong University, where they were attending a clinic for routine examination.
For all study participants, smoking status was defined as 'never' (smoked <100 cigarettes in their lifetime) and 'ever' a smoker (smoked !100 cigarettes in their lifetime); alcohol drinking status was defined as 'never' (never drinks alcohol) and 'ever' an alcohol drinker (drinks any alcoholic drinks). All study participants were paid for their time. Any family history of cancer was recorded for all study participants. After giving written informed consent, each participant donated 20 ml of blood that was collected in heparinized tubes containing a minimum of 3 IU ammonium heparin. The samples were stored at 4 C until analysis.
Written informed consent was obtained from all study participants according to the Declaration of Helsinki, and the study protocol was approved by the Research Ethics Board of the First Affiliated Hospital of Xi'an Jiaotong University (no. XJU2009008).
Genotyping analysis
Genomic DNA was extracted from peripheral blood leukocytes in 10 ml of peripheral blood using a commercially available QIAamp Õ DNA Mini Kit (QIAGEN, Valencia, CA, USA). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was conducted to detect the three SNPs of the VEGF gene (À634 G/C, þ936 C/T and þ1612 G/A). The PCR primers were designed and prepared in-house based on the Genbank reference sequence for the VEGF gene 23 and were as follows: À634 G/C: 5 0 -GTA GCA AGA GCT CCA GAG AGA AGT-3 0 (forward) and 5 0 -TGG ACG AAA AGT TTC AGT GCG ACG-3 0 (reverse); þ936 C/T: 5 0 -CTC GGT GAT TTA GCA GCA AG-3 0 (forward) and 5 0 -CTC GGT GAT TTA GCA GCA AG-3 0 (reverse); þ1612 G/A: 5 0 -CAC ATG CTG CAC GCG CAT CTC A-3 0 (forward) and 5 0 -ACC CCA GGA AGG GGA GCA GGA-3 0 (reverse). The PCR reactions were carried out in a 20-ml reaction volume containing 100 ng genomic DNA, 25 pmol/l each primer, 0.2 mmol/l of each deoxyribonucleotide triphosphate, 10 mmol/l Tris-HCl (pH 8.3), 50 mmol/l KCl, 1.5 mmol/l MgCl 2 and 1 unit of Taq DNA polymerase (all reagents from TaKaRa Shuzo, Otsu, Japan). The PCR cycling programme involved preliminary denaturation at 94 C for 5 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 62 C for 30 s, elongation at 72 C for 30 s, and a final elongation step at 72 C for 10 min. The PCR products were digested overnight with the appropriate restriction enzymes (New England Biolabs, Beverly, MA, USA), which were BsmFI, NlaIII, and MnlI for the À634 G/C, þ936 C/T and þ1612 G/A polymorphisms, respectively. The PCR products were separated on a 1% agarose gel and the digested products were visualized on a 2% agarose gel stained with ethidium bromide and photographed using a Digital Imaging System (Model IS-1000; Alpha Innotech, San Leandro, CA, USA). The VEGF À 634G allele was cut into two fragments of 193 and 111 base pairs (bp), whereas the VEGF À 634C allele remained uncut with a length of 304 bp. The VEGF þ 936T allele was cut into two fragments of 122 and 86 bp, whereas the VEGF þ 936C allele remained uncut with a length of 208 bp. The VEGF þ 1612A allele was cut into two fragments of 112 and 105 bp, whereas the VEGF þ 1612G allele remained uncut with a length of 217 bp.
Statistical analyses
All statistical analyses were performed using the SAS Õ software package, version 8.0 (SAS Institute, Cary, NC, USA). The VEGF allele and genotype frequencies in patients with gliomas were compared with those in the healthy control subjects using the 2 -test. Univariate and multivariate logistic regression analyses were used to calculate crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between the genotypes and the risk of glioma. The data were stratified into subgroups based on the WHO histological type and tumour grade of the gliomas. The Hardy-Weinberg test of genetic equilibrium was applied using the 2 -test to ensure that there was no significant difference between observed and expected genotype frequencies. A P-value < 0.05 was considered statistically significant.
Results
This hospital-based case-control study included 880 patients with gliomas and 880 age-and sex-matched healthy control subjects. The clinical and demographic characteristics of the patients with gliomas and the control subjects are shown in Table 1 . There were no significant differences in sex distribution, age, smoking status, drinking status and family history of cancer between the patients with gliomas and the control subjects.
Patients with gliomas had a significantly higher frequency of the À634 CC genotype compared with the control subjects (OR 1.35, 95% CI 1.05, 1.75; P ¼ 0.02) ( Table 2) . When stratified by the WHO histological type of glioma, patients with glioblastoma had a significantly higher frequency of the À634 CC genotype compared with patients with the other histological types of glioma (OR 1.39, 95% CI 1.04, 1.87; P ¼ 0.03) ( Table 3) . When stratified by the WHO grade of glioma, patients with grade IV glioma had a significantly higher frequency of the À634 CC genotype compared with patients with other grades of tumour (OR 1.39, 95% CI 1.04, 1.86; P ¼ 0.03) ( Table 4 ).
Patients with gliomas had a significantly higher frequency of the þ936 TT genotype compared with the control subjects (OR 1.73, 95% CI 1.20, 2.48; P ¼ 0.003) ( Table  2) . When stratified by the WHO histological type of glioma, patients with glioblastoma patients had a significantly higher frequency of the þ936 TT genotype compared with patients with the other histological types of glioma (OR 1.52, 95% CI 1.04, 2.23; P ¼ 0.03) ( Table 3) . When stratified by the WHO grade of glioma, patients with grade IV glioma had a significantly higher frequency of the þ936 TT genotype compared with patients with other grades of tumour (OR 1.51, 95% CI 1.04, 2.21; P ¼ 0.03) ( Table 4 ).
The data shown in Table 2 indicate that the þ1612G/A polymorphisms were unlikely to be associated with glioma risk. When stratified by the WHO histological type and grade of glioma, there were statistically significant results observed (Tables 3 and 4 ). 
Discussion
The present study investigated the possible association between three VEGF gene polymorphisms and the risk of glioma in a Han Chinese population of patients with glioma and healthy control subjects. Patients with gliomas had a significantly higher frequency of the À634 CC and þ936 TT genotypes compared with control subjects. These two genotypes were also significantly more common in patients with glioblastomas and in patients with grade IV glioma. There was no evidence in the present study that the þ1612G/A polymorphisms were associated with glioma risk. The exact mechanism by which the VEGF gene polymorphisms affect glioma risk remains unclear. VEGF is an important angiogenic factor for tumour progression because it increases endothelial cell proliferation and remodels the extracellular matrix in blood vessels. 27 VEGF gene expression is elevated in a wide variety of solid tumours. 28 Inhibition of VEGF activity is able to reduce angiogenesis and tumour growth. 29 Some studies have shown that high levels of VEGF gene expression and increased microvessel density in tumours were associated with advanced stage disease and worse prognosis for various types of tumours. [30] [31] [32] Several polymorphisms in the VEGF gene have been reported to affect the expression of the gene. 33 Three potentially functional SNPs (À634 G/C, þ936 C/T and þ1612 G/A) in the 3 0 UTR of the VEGF gene were shown to affect plasma VEGF levels. 17 Renner et al. 17 first identified the VEGF þ 936 C/T gene polymorphism and found that the VEGF þ 936 T allele led to significantly lower plasma VEGF protein levels in healthy young men.
Polymorphisms of the VEGF gene have been reported to be associated with many Table 2 . Allele and genotype frequencies of the three vascular endothelial growth factor gene single nucleotide polymorphisms (À634 G/C, þ936 C/Tand þ1612 G/A) among patients with gliomas (n ¼ 880) and healthy control subjects (n ¼ 880). other cancers. For example, a case-control study in a US population suggested that the VEGF þ 936 C/T polymorphism may be a marker for susceptibility to gastric cancer. 34 Another case-control study suggested that the VEGF þ 936 C/T polymorphism reduces BRCA1-associated breast cancer risk in Polish women. 35 A case-control study in a Spanish population suggested that the VEGF þ 936 C/T polymorphism might be an important genetic marker of susceptibility to breast cancer. 36 In a case-control study in a Korean population, the VEGF þ 936 C/T polymorphism appeared to be a genetic determinant for colon cancer. 37 A meta-analysis of 12 epidemiological studies, which included 2770 colorectal cancer cases and 2568 control subjects, suggested that the VEGF À 460 T/ C, À634 G/C and À2578 C/A gene polymorphisms were associated with the risk of colorectal cancer. 38 A case-control study in an ethnic Han group from northern China suggested that the SNP markers at the À2578C and 936C loci of the VEGF gene may serve as biological markers of lung cancer. 39 A growing number of SNPs have been found to be associated with glioma susceptibility. For example, a meta-analysis of 11 published studies suggested that the XRCC1 Arg399Gln polymorphism may contribute to the susceptibility of glioma in an Asian population. 40, 41 A case-control study has shown that XRCC1 Gln399Arg, XRCC1 Arg194Trp, XRCC3 Thr241Met and ERCC5 Asp1558His were associated with a risk of gliomas. 42 A meta-analysis of 11 case-control studies, which included 2404 patients with gliomas and 6379 control subjects, suggested that the GSTP1 A114V genotype was associated with a risk of gliomas. 43 A case-control study suggested that the EGF þ61G AA genotype was associated with a higher glioma risk in a Chinese population. 44 Another case-control study in a Chinese population observed that the XPD 751 Gln/Gln genotype was associated with glioma susceptibility. 45 This present study had a number of limitations that should be taken into account when interpreting the findings. First, this was a hospital-based case-control study, so selection bias cannot be excluded and the participants may not be representative of the general population. Secondly, this present study only analysed three SNPs. Thirdly, further research is required to delineate the precise mechanisms involved and, potentially, to facilitate the design of effective clinical trials. Finally, these results should be interpreted with caution because the population was exclusively from China, which reduces the possibility of confounding from ethnicity, but it does not permit extrapolation of the results to other ethnic groups.
Genotype
In conclusion, this present study demonstrated that the VEGF À 634 CC and þ936 TT genotypes were associated with a higher risk of glioma in a Han Chinese population. Further well-designed studies with larger sample sizes using different ethnicities are needed to further assess the associations between VEGF gene polymorphisms and the risk of glioma.
